Sanford C. Bernstein lowered shares of Shire (NASDAQ:SHPG) from an outperform rating to a market perform rating in a research note published on Tuesday morning, MarketBeat Ratings reports.
A number of other research analysts have also issued reports on the company. Royal Bank of Canada set a $188.00 price objective on Shire and gave the company a buy rating in a research report on Thursday, July 19th. BidaskClub lowered Shire from a hold rating to a sell rating in a research report on Thursday, August 16th. Cantor Fitzgerald set a $222.00 price objective on Shire and gave the company a buy rating in a research report on Tuesday, July 31st. Kepler Capital Markets restated a buy rating on shares of Shire in a research report on Friday, May 11th. Finally, ValuEngine upgraded Shire from a sell rating to a hold rating in a research report on Friday, August 24th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of $200.75.
NASDAQ:SHPG opened at $166.29 on Tuesday. Shire has a 12-month low of $123.73 and a 12-month high of $177.51. The company has a market cap of $51.08 billion, a P/E ratio of 10.98, a P/E/G ratio of 1.49 and a beta of 1.22. The company has a quick ratio of 1.02, a current ratio of 1.55 and a debt-to-equity ratio of 0.45.
Shire (NASDAQ:SHPG) last released its quarterly earnings data on Tuesday, July 31st. The biopharmaceutical company reported $3.88 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.67 by $0.21. Shire had a return on equity of 13.22% and a net margin of 31.06%. The business had revenue of $3.92 billion during the quarter. During the same quarter in the prior year, the firm earned $3.73 EPS. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. equities analysts expect that Shire will post 15.29 EPS for the current fiscal year.
The firm also recently declared a dividend, which will be paid on Friday, October 19th. Shareholders of record on Friday, September 7th will be given a dividend of $0.168 per share. The ex-dividend date is Thursday, September 6th. Shire’s dividend payout ratio (DPR) is presently 2.24%.
A number of hedge funds have recently made changes to their positions in SHPG. Centaurus Financial Inc. acquired a new position in Shire during the 2nd quarter worth $102,000. North Star Investment Management Corp. acquired a new position in Shire during the 2nd quarter worth $106,000. Valeo Financial Advisors LLC acquired a new position in Shire during the 2nd quarter worth $129,000. Cornerstone Wealth Management LLC acquired a new position in Shire during the 2nd quarter worth $145,000. Finally, Wolverine Asset Management LLC acquired a new position in Shire during the 2nd quarter worth $168,000. Institutional investors own 17.89% of the company’s stock.
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Read More: How to Invest in Marijuana Stocks
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.